1. Short title
This Act may be cited as the “International Pharmaceutical Transparency Act of 2019”.
International Pharmaceutical Transparency Act of 2019
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to require the label of a drug to list the country of origin of each of the drug’s active ingredients.
2. Country-of-origin labeling for active ingredients in drugs
Misbranding— Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following:
“(ee) If it is a drug and its label fails to list the country of origin of each of its active ingredients.”
Applicability— Section 502(ee) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), applies beginning on the day that is 6 months after the date of enactment of this Act.